Cuminaldehyde
Cuminaldehyde[1] | |
---|---|
IUPAC name 4-(1-Methylethyl)benzaldehyde | |
Other names Cuminaldehyde | |
Identifiers | |
CAS number | 122-03-2 |
ChemSpider | 21106431 |
UNII | O0893NC35F |
KEGG | C06577 |
ChEMBL | CHEMBL161577 |
RTECS number | CU7000000 |
Jmol-3D images | Image 1 |
| |
| |
Properties | |
Molecular formula | C10H12O |
Molar mass | 148.20 g mol−1 |
Appearance | Colorless oil |
Density | 0.978 g/cm3 |
Boiling point | 235.5 °C; 455.9 °F; 508.6 K |
Solubility in water | Insoluble |
Hazards | |
R-phrases | R22 |
S-phrases | S36/37 |
NFPA 704 |
2
1
0
|
Flash point | 93 °C; 199 °F; 366 K |
Related compounds | |
Related compounds | Benzaldehyde Cumene Cuminol |
(verify) (what is: / ?) Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa) | |
Infobox references | |
Cuminaldehyde, or 4-isopropylbenzaldehyde, is a natural organic compound with the molecular formula C10H12O. It is a benzaldehyde with an isopropyl group substituted in the 4-position.
Cuminaldehyde is a constituent of the essential oils of eucalyptus, myrrh, cassia, cumin and others.[1] It has a pleasant smell and contributes to the aroma of these oils. It is used commercially in perfumes and other cosmetics.
It has been shown that cuminaldehyde, as a small molecule, inhibits the fibrillation of alpha-synuclein,[2] which, if aggregated, forms insoluble fibrils in pathological conditions characterized by Lewy bodies, such as Parkinson's disease, dementia with Lewy bodies[3] and multiple system atrophy.[4]
Cuminaldehyde can be prepared synthetically by the reduction of 4-isopropylbenzoyl chloride or by the formylation of cumene.
The thiosemicarbazone of cuminaldehyde has antiviral properties.
References
- ↑ 1.0 1.1 Merck Index, 11th Edition, 2623
- ↑ Morshedi D, Aliakbari F, (Spring 2012). "The Inhibitory Effects of Cuminaldehyde on Amyloid Fibrillation and Cytotoxicity of Alpha-synuclein". modares journal of medical sciences: pathobiology 15 (1): 45–60.
- ↑ Arima K, Uéda K, Sunohara N, Hirai S, Izumiyama Y, Tonozuka-Uehara H, Kawai M (October 1998). "Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies". Brain Res. 808 (1): 93–100. doi:10.1016/S0006-8993(98)00734-3. PMID 9795161.
- ↑ Arima K, Uéda K, Sunohara N, Arakawa K, Hirai S, Nakamura M, Tonozuka-Uehara H, Kawai M (November 1998). "NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy". Acta Neuropathol. 96 (5): 439–44. doi:10.1007/s004010050917. PMID 9829806.